At Chiasma, we remain resilient in the face of challenges. Leveraging our delivery technology, Transient Permeability Enhancer (TPE®), we work every day to create innovative solutions to improve the lives of patients with rare or serious diseases. It is our mission to develop and commercialize alternative treatment options to injectable therapies so that we may provide the patients we serve with greater independence to live their lives as they choose. Currently, we are focused on developing octreotide capsules as a potential maintenance treatment for adults with acromegaly.

Our Values

We leverage our resiliency in the face of challenges to pursue our mission.

We embed integrity and energy in all we do to achieve superior results built on a foundation for sustainable and profitable growth.

We utilize our innovative technology to develop novel solutions that address significant unmet medical needs.

We focus on the impact of our actions and are responsible to patients, our community and our people.

We act with speed, efficiency and accountability to benefit patients, employees, and shareholders.

Our Values

Persistence

We leverage our resiliency in the face of challenges to pursue our mission.

Passion for Results

We embed integrity and energy in all we do to achieve superior results built on a foundation for sustainable and profitable growth.

Ingenuity

We utilize our innovative technology to develop novel solutions that address significant unmet medical needs.

Commitment to People

We focus on the impact of our actions and are responsible to patients, our community and our people.

Sense of Urgency

We act with speed, efficiency and accountability to benefit patients, employees, and shareholders.

Management Team

Chiasma is led by an experienced team with deep knowledge of the pharmaceutical industry, from research and development to commercialization.

Raj Kannan

Raj Kannan

Chief Executive Officer
Mark Fitzpatrick

Mark J. Fitzpatrick

President
William Ludlam

William Ludlam, M.D., Ph.D.

Senior VP Clinical Development and Medical Affairs
Anand Varadan

Anand Varadan

Chief Commercial Officer
Drew Enamait

Drew Enamait

VP Finance & Administration
Lee Giguere

Lee Giguere

VP General Counsel
Shoshie Katz

Shoshie Katz

VP Quality Assurance & Regulatory Affairs
Gary Patou

Gary Patou, M.D.

Head of Clinical

Board of Directors

Dave Stack

Chairman of the Board

Raj Kannan

CEO and Director

Todd Foley

Director

Bard Geesaman, M.D., Ph.D.

Director

Roni Mamluk, Ph.D.

Director

Scott Minick

Director

John A. Scarlett, M.D.

Director

John F. Thero

Director

Clinical Advisors

Our team of advisors includes academic and clinical leaders with world-renowned reputations in the field of endocrinology.

Shlomo Melmed, M.D.

Senior Vice President, Academic Affairs, Dean of the Medical Faculty and Director, Burns and Allen Research Institute of Cedars-Sinai Medical Center; Los Angeles, California

Christian J. Strasburger, M.D.

Professor of Medicine, Chief, Division of Clinical Endocrinology, Department of Medicine for Endocrinology, Diabetes and Nutritional Medicine; Charité-Universitätsmedizin, Campus Mitte; Berlin, Germany